Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

Journal of the American College of Cardiology

Volumn 73, Issue 4, 2019, Pages 387-396

  Szarek, Michael ^a   White, Harvey D ^b   Schwartz, Gregory G ^c   Alings, Marco ^d   Bhatt, Deepak L ^e   Bittner, Vera A ^f   Chiang, Chern En ^g   Diaz, Rafael ^h   Edelberg, Jay M ⁱ   Goodman, Shaun G ^j   Hanotin, Corinne ⁱ   Harrington, Robert A ^k   Jukema, J Wouter ^l   Kimura, Takeshi ^m   Kiss, Robert Gabor ⁿ   Lecorps, Guillaume ⁱ   Mahaffey, Kenneth W ^k   Moryusef, Angèle ⁱ   Pordy, Robert ^o   Roe, Matthew T ^p,q   Tricoci, Pierluigi ^q   Xavier, Denis ^r   Zeiher, Andreas M ^s   Steg, Ph Gabriel ^t,u   more..

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d AMPHIA HOSPITAL   (Netherlands)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h Sanatorio Parque e Instituto Cardiovascular de Rosario   (Argentina)

ⁱ SANOFI   (France)

^j UNIVERSITY OF ALBERTA   (Canada)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ Magyar Honvedseg Egeszsegugyi Kozpont Szemeszeti Osztaly   (Hungary)

^o REGENERON PHARMACEUTICALS INC   (United States)

^p DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q DUKE UNIVERSITY MEDICAL CENTER   (United States)

^r ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^s GOETHE UNIVERSITY   (Germany)

^t BICHAT HOSPITAL   (France)

^u ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

acute coronary syndrome; alirocumab; total events

Indexed keywords

ALIROCUMAB; ATORVASTATIN; PLACEBO; ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCLONAL ANTIBODY;

AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FATALITY; FEMALE; FRAILTY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNSTABLE ANGINA PECTORIS; ACUTE CORONARY SYNDROME; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED;

ACUTE CORONARY SYNDROME; AGED; ANTIBODIES, MONOCLONAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 85060287356     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.10.039     Document Type: Article

References (11)

1. Tikkanen, M.J., Szarek, M., Fayyad, R., et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol 54 (2009), 2353–2357.
2. Murphy, S.A., Cannon, C.P., Wiviott, S.D., McCabe, C.H., Braunwald, E., Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 54 (2009), 2358–2362.
3. LaRosa, J.C., Deedwania, P.C., Shepherd, J., et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 105 (2010), 283–287.
4. Murphy, S.A., Cannon, C.P., Blazing, M.A., et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT Trial. J Am Coll Cardiol 67 (2016), 353–361.
5. Schwartz, G.G., Fayyad, R., Szarek, M., DeMicco, D., Olsson, A.G., Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol 24 (2017), 1294–1296.
6. Roe, M.T., Armstrong, P.W., Fox, K.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
7. White, H.D., Huang, Z., Tricoci, P., et al. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. J Am Heart Assoc 3 (2014), 1–9.
8. Schwartz, G.G., Steg, P.G., Szarek, M., et al., for the ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379 (2018), 2097–2107.
9. Schwartz, G.G., Bessac, L., Berdan, L.G., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168 (2014), 682–689.
10. Liu, L., Wolfe, R.A., Huang, X., Shared frailty models for recurrent events and a terminal event. Biometrics 60 (2004), 747–756.
11. Rondeau, V., Mathoulin-Pelissier, S., Jacqmin-Gadda, H., Brouste, V., Soubeyran, P., Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics 8 (2007), 708–721.